AROMASIN is indicated for adjuvant cure of postmenopausal women with estrogen-receptor beneficial early breast cancer that have acquired two to three years of tamoxifen and so are switched to AROMASIN for completion of a complete of five consecutive a long time of adjuvant hormonal therapy [see Clinical Scientific tests (fourteen.1)].AROMASIN reall